Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement.
On February27, 2018, Supernus Pharmaceuticals,Inc. (the “Company”) and Rockside-700 LLC (“Rockside”) entered into a Lease Agreement (the “Lease”) for the Company’s new headquarters to be located at 700 Quince Orchard Road, Gaithersburg, Maryland (the “Premises”). On November28, 2018, the Company notified Rockside that the Company intended to terminate the Lease in the event that the parties were unable to resolve a dispute over the provision of certain facilities included in the approved site plan. On December13, 2018 (the “Termination Date”), Rockside notified the Company that it accepted the Company’s termination notice and the Lease was thereby terminated. As of the Termination Date, the term of the Lease had not commenced and the Company had not occupied the premises. The Company has not incurred any material termination penalties in connection with termination of the Lease.
Item 8.01 Other Events.
On December14, 2018, the Company issued a press release announcing that the United States Food and Drug Administration approved the Company’s supplemental new drug application to expand the Oxtellar XR® label to include monotherapy treatment for partial-onset seizures. A copy of this press releases is furnished as Exhibit99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
The following document is furnished as an Exhibit to Item 8.01 hereof:
Exhibit99.1 — Press Release Dated December14, 2018.
SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a18-41863_1ex99d1.htm EX-99.1 Exhibit 99.1 Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy ROCKVILLE,…
To view the full exhibit click
About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.